All In Biotech

Drug Trial Radar · NCT02090764

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

A Phase III 2 Arms, Multicenter, Randomised, Double-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo

Last checked: Nov 19, 2026Latest source record: Aug 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 412 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

412

Actual

Start

Jun 2014

Primary completion

May 2015

Study completion May 2015

Sponsor

Lead sponsor
Ferrer Internacional S.A.Industry
Sponsor type
Industry
First posted
Mar 18, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 2 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is multicenter, randomised, placebo controlled, parallel, double blinded , superiority clinical study comparing ozenoxacin cream versus placebo, in patients with a clinical diagnosis of non-bullous or bullous impetigo.

Conditions

  • Impetigo

Interventions

  • OzenoxacinDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical SuccessTime frame: Visit 3 (Day 6-7)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Caparra Internal Medicine Center

    Rio Grande, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.